May we actually help clinicians select the best systemic treatment for patients with intermediate-stage hepatocellular carcinoma?

Liver Int. 2024 Feb;44(2):272-274. doi: 10.1111/liv.15781.

Authors

Edoardo G Giannini^{1

2}, Mario Strazzabosco^{2

3}

Affiliations

¹ Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.
² Digestive Diseases Section, Department of Internal Medicine, Liver Center, Yale University School of Medicine, New Haven, Connecticut, USA.
³ Smilow Cancer Hospital and Liver Cancer Program, New Haven, Connecticut, USA.

PMID: 38289589
DOI: 10.1111/liv.15781

No abstract available

Publication types

Editorial

MeSH terms

Carcinoma, Hepatocellular* / drug therapy
Humans
Liver Neoplasms* / drug therapy